Geron is a clinical-stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Imetelstat is designed to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.
Net income (Q1, 2018)
EBIT (Q1, 2018)
Market capitalization (14-Jun-2018)
Closing share price (14-Jun-2018)
|USD||Q2, 2014||Q3, 2014||Q1, 2015||Q2, 2015||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017|
|(9.4 m)||27.2 m||(8.8 m)||(8.6 m)||(3.6 m)||(7.2 m)|
|1.2 m||2.4 m||1.2 m||957 k||574 k||396 k||235 k||271 k||308 k|